(S)-2-tert-butoxycarbonylamino-3-[4-(2,6-dichlorobenzoylamino)phenyl]propionic acid methyl ester | 219496-61-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-tert-butoxycarbonylamino-3-[4-(2,6-dichlorobenzoylamino)phenyl]propionic acid methyl ester
• 英文别名: methyl (2S)-3-[4-[(2,6-dichlorobenzoyl)amino]phenyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate
• CAS: 219496-61-4
• 化学式: C₂₂H₂₄Cl₂N₂O₅
• 分子量: 467.349
• InChiKey: VIOHGZMHLYLDGG-KRWDZBQOSA-N

物化性质

• 沸点：
  545.6±50.0 °C(Predicted)
• 密度：
  1.309±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  93.7
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (S)-2-tert-butoxycarbonylamino-3-[4-(2,6-dichlorobenzoylamino)phenyl]propionic acid methyl ester 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 生成 4-[[(2,6-Dichlorophenyl)carbonyl]amino]-N-[(2-ethyl-6-methylphenyl)carbonyl]-L-phenylalanine methyl ester
  参考文献：
  名称：

  N-Aroyl-l-Phenylalanine Derivatives as VCAM/VLA-4 Antagonists

  摘要：

  A series of N-benzoyl-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine derivatives was prepared in order to optimize the substitution on the N-benzoyl moiety for VCAM/VLA-4 antagonist activity. Disubstitution in the 2- and 6-positions is favored and a range of small alkyl and halogen are tolerated. A model of the bioactive conformation of these compounds is proposed. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00387-6
• 作为产物：
  描述：

  BOC-L-4-硝基苯丙氨酸 在 sodium carbonate 、 氯化铵 、 N,N-二异丙基乙胺 、 锌 作用下， 以 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 30.0h， 生成 (S)-2-tert-butoxycarbonylamino-3-[4-(2,6-dichlorobenzoylamino)phenyl]propionic acid methyl ester
  参考文献：
  名称：

  CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY

  摘要：

  该发明涉及公式I的壳聚糖聚合物衍生物： 及其药用可接受的盐和酯，其中Y、X 1 、X 4 、R1、R2和n在详细说明和权利要求中有定义。公式I的壳聚糖聚合物衍生物与α4β1和αVβ3整合素二聚体结合或结合，并可用于传递制剂以将药物、核酸或其他治疗化合物传递到表达这些整合素的组织或细胞中。

  公开号：

  US20130197205A1

文献信息

• Lipid Compounds Targeting VLA-4
  申请人：BOYLAN John Frederick

  公开号：US20130079383A1

  公开（公告）日：2013-03-28

  The invention relates to the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein n, G, W, X, Y, and R1 are defined in the detailed description and claims. The compounds of formula I bind to or associate with VLA-4 and can be used in delivery formulations to deliver drugs, nucleic acids, or other therapeutic compounds to tissues or cells expressing VLA-4.

  这项发明涉及公式I的化合物： 以及其药用可接受的盐和酯，其中n、G、W、X、Y和R1在详细说明和索赔中有定义。公式I的化合物与VLA-4结合或与之相关，并可用于传递制剂，将药物、核酸或其他治疗化合物传递到表达VLA-4的组织或细胞中。
• N-aroylphenylalanine derivative VCAM-1 inhibitors
  申请人：Hoffman-La Roche Inc.

  公开号：US06229011B1

  公开（公告）日：2001-05-08

  Compounds of the formula: are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4.

  揭示了具有以下化学式的化合物，这些化合物具有作为VCAM-1和表达VLA-4的细胞之间结合抑制剂的活性。这些化合物对于治疗症状和/或损害与VCAM-1与表达VLA-4的细胞结合有关的疾病是有用的。
• [EN] INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4<br/>[FR] CONJUGUÉS D'ANTAGONISTES D'INTÉGRINE POUR CIBLER DES CELLULES EXPRIMANT LE VLA-4
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013110680A1

  公开（公告）日：2013-08-01

  The invention relates to compounds of formula I: wherein R1, R2, and n are defined in the detailed description and claims. In particular, the present invention relates to the compounds of formula I for use in the manufacture and delivery of conjugated moieties such as small molecules, peptides, nucleic acids, fluorescent moieties, and polymers which are linked to VLA-4 integrin antagonists to target cells expressing VLA-4.

  该发明涉及以下式I的化合物：其中R1、R2和n在详细说明和权利要求中有定义。具体而言，本发明涉及式I的化合物，用于制造和传递共轭基团，如小分子、肽、核酸、荧光基团和聚合物，这些基团与VLA-4整合素拮抗剂连接，以靶向表达VLA-4的细胞。
• N-alkanoylphenylalanine derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06455550B1

  公开（公告）日：2002-09-24

  Compounds of the formula: are disclosed which have activity as inhibitors of binding between VCAM-1 and cells expressing VLA-4. Such compounds are useful for treating diseases whose symptoms and/or damage are related to the binding of VCAM-1 to cells expressing VLA-4.

  揭示了具有以下化学式的化合物，这些化合物具有作为VCAM-1和表达VLA-4的细胞之间结合抑制剂的活性。这些化合物对于治疗那些症状和/或损害与VCAM-1与表达VLA-4的细胞结合有关的疾病是有用的。
• Inhibitors of &agr;4&bgr;1 mediated cell adhesion
  申请人：Pharmacia & Upjohn Company

  公开号：US06685617B1

  公开（公告）日：2004-02-03

  The present invention relates to compound of formula (I), that are potent inhibitors of &agr;4&bgr;1 mediated adhesion to either VCAM or CS-1 and which could be useful for the treatment of inflammatory diseases. Specifically, the molecules of the present invention can be used for treating or preventing &agr;4&bgr;1 adhesion mediated conditions in a mammal such as a human. This method may comprise administering to a mammal or a human patient an effective amount of the compound or composition as explained in the present specification.

  本发明涉及式(I)的化合物，它们是α4β1介导的对VCAM或CS-1的黏附的有效抑制剂，可用于治疗炎症性疾病。具体来说，本发明的分子可用于治疗或预防哺乳动物，如人类，中的α4β1介导的黏附状况。该方法可能包括向哺乳动物或人类患者施用本说明书中所述的化合物或组合物的有效量。